mvasi 100 mg concentrado para solucion para perfusion
tecnofarma s.a. - droguerÍa - bevacizumab - concentrado para solucion para perfusion - 100 mg - por vial 100.00 mg - - bevacizumab
mvasi 400mg concentrado para solucion para perfusion
varifarma peru s.a.c. - droguerÍa - bevacizumab - concentrado para solucion para perfusion - 400 mg - por vial 16.00 ml - - bevacizumab
bevanatrelle®
hetero biopharma limited, bloque iii-a (planta baja) y bloque iii-a (primer piso) - bevacizumab - solución concentrada para infusión iv - 25 mg/ml
mvasi
amgen technology (ireland) uc irlanda - cada ml de concentrado contiene 25mg de bevacizumab. - concentrado para solucion para perfusion - cada vial contiene 25 mg/ml de bevacizumab
cetomedica 20 mg/ml concentrado para solucion para perfusion efg
regiomedica gmbh - irinotecan hidrocloruro trihidrato - excipientes: sorbitol,hidroxido de sodio (e-524) - otros agentes antineoplÁsicos - otros agentes antineoplásicos - irinotecán
irinotecan regiomedica 20 mg/ml concentrado para solucion para perfusion efg
regiomedica gmbh - irinotecan hidrocloruro trihidrato - excipientes: sorbitol,hidroxido de sodio (e-524) - otros agentes antineoplÁsicos - otros agentes antineoplásicos - irinotecán
irinotecan sandoz 20 mg/ml concentrado para solucion para perfusion efg
sandoz farmaceutica s.a. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
lonsurf
les laboratoires servier - trifluridine, tipiracil clorhidrato de - neoplasias colorrectales - agentes antineoplásicos - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - neoplasmas estomacales - agentes antineoplásicos - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
avastin®
f.hoffmann-la roche s.a. [ch] switzerland - bevacizumab 25mg/ml 100mg/4ml 400mg/16ml - concentrado para soluciÓn para infusiÓn - cada vial de 4ml contiene: bevacizumab 100,0 mg cada vial de 16 ml contiene: bevacizumab 400,0 mg